Salmi T
Acta Endocrinol Suppl (Copenh). 1980;233:37-43.
A review of literature, mainly the results of studies conducted in America, shows obesity, diabetes mellitus, hypertension, infertility/nulliparity, late menopause, high endogenous oestrogen production, and the use of oestrogens to be the main factors associated with the development of endometrial carcinoma. Whilst most of these factors undoubtedly apply irrespective of country, doubt in Finland about the use of oestrogens being a risk factor was one of the reasons prompting the study reported here. This study, which was conducted in Turku, Finland, involved 318 endometrial carcinoma patients, 282 of whom could be paired with controls matched for age, height and weight, and social class. The data show the use of oestrogens per se not to be a risk factor. The fact that there appears to be a risk in America, where most of the oestrogenic preparations used are based on conjugated equine oestrogens, but not in Finland, where the preference is for preparations based on oestriol and oestradiol and where conjugated oestrogen preparations are relatively rarely used, supports the hypothesis that the risk depends on the type of oestrogen used.
文献综述,主要是在美国进行的研究结果表明,肥胖、糖尿病、高血压、不孕/未生育、绝经延迟、内源性雌激素产生过多以及雌激素的使用是与子宫内膜癌发生相关的主要因素。虽然这些因素中的大多数无疑在任何国家都适用,但芬兰对雌激素使用是否为危险因素存在疑问,这是促使进行本研究报告的原因之一。这项在芬兰图尔库进行的研究涉及318例子宫内膜癌患者,其中282例可与年龄、身高、体重和社会阶层相匹配的对照组配对。数据表明,雌激素本身并非危险因素。在美国似乎存在风险,美国使用的大多数雌激素制剂是以结合马雌激素为基础的,但在芬兰却没有风险,芬兰更倾向于使用基于雌三醇和雌二醇的制剂,且结合雌激素制剂相对很少使用,这一事实支持了风险取决于所用雌激素类型的假说。